SZSE:002437 (China)
Â
Class A
Â¥
2.03
(-0.49%)
May 24
Current and historical daily PE Ratio for Harbin Gloria Pharmaceuticals Co Ltd (
SZSE:002437
) from 2010 to May 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Harbin Gloria Pharmaceuticals stock (SZSE:002437) PE ratio as of May 24 2024 is 29.
More Details
Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) PE Ratio (TTM) Chart
Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) PE Ratio (TTM) Historical Data
View and export this data going back to 2010. Start your Free Trial
Total 1190
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Harbin Gloria Pharmaceuticals PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-24 | 29.0 | 2024-03-15 | 39.5 |
| 2024-05-23 | 29.1 | 2024-03-14 | 39.1 |
| 2024-05-22 | 29.9 | 2024-03-13 | 38.7 |
| 2024-05-21 | 30.0 | 2024-03-12 | 39.1 |
| 2024-05-20 | 30.6 | 2024-03-11 | 38.2 |
| 2024-05-17 | 30.3 | 2024-03-08 | 37.3 |
| 2024-05-16 | 30.4 | 2024-03-07 | 37.5 |
| 2024-05-15 | 30.7 | 2024-03-06 | 37.8 |
| 2024-05-14 | 30.9 | 2024-03-05 | 37.6 |
| 2024-05-13 | 30.7 | 2024-03-04 | 38.7 |
| 2024-05-10 | 30.7 | 2024-03-01 | 38.2 |
| 2024-05-09 | 31.1 | 2024-02-29 | 38.2 |
| 2024-05-08 | 31.0 | 2024-02-28 | 37.5 |
| 2024-05-07 | 31.1 | 2024-02-27 | 39.3 |
| 2024-05-06 | 31.3 | 2024-02-26 | 38.5 |
| 2024-04-30 | 31.0 | 2024-02-23 | 38.5 |
| 2024-04-29 | 30.6 | 2024-02-22 | 37.5 |
| 2024-04-26 | 29.9 | 2024-02-21 | 37.1 |
| 2024-04-25 | 29.3 | 2024-02-20 | 36.7 |
| 2024-04-24 | 28.9 | 2024-02-19 | 36.2 |
| 2024-04-23 | 28.7 | 2024-02-08 | 35.8 |
| 2024-04-22 | 28.4 | 2024-02-07 | 32.9 |
| 2024-04-19 | 28.4 | 2024-02-06 | 33.6 |
| 2024-04-18 | 28.4 | 2024-02-05 | 32.5 |
| 2024-04-17 | 29.1 | 2024-02-02 | 36.0 |
| 2024-04-16 | 27.4 | 2024-02-01 | 37.3 |
| 2024-04-15 | 30.1 | 2024-01-31 | 37.5 |
| 2024-04-12 | 29.7 | 2024-01-30 | 38.9 |
| 2024-04-11 | 30.1 | 2024-01-29 | 40.4 |
| 2024-04-10 | 30.1 | 2024-01-26 | 41.6 |
| 2024-04-09 | 30.7 | 2024-01-25 | 41.3 |
| 2024-04-08 | 30.0 | 2024-01-24 | 39.8 |
| 2024-04-03 | 30.9 | 2024-01-23 | 38.9 |
| 2024-04-02 | 31.0 | 2024-01-22 | 38.9 |
| 2024-04-01 | 30.9 | 2024-01-19 | 41.6 |
| 2024-03-29 | 30.6 | 2024-01-18 | 42.0 |
| 2024-03-28 | 30.4 | 2024-01-17 | 42.4 |
| 2024-03-27 | 38.2 | 2024-01-16 | 43.5 |
| 2024-03-26 | 38.5 | 2024-01-15 | 43.8 |
| 2024-03-25 | 38.7 | 2024-01-12 | 43.8 |
| 2024-03-22 | 39.6 | 2024-01-11 | 44.4 |
| 2024-03-21 | 40.5 | 2024-01-10 | 43.6 |
| 2024-03-20 | 40.7 | 2024-01-09 | 44.0 |
| 2024-03-19 | 40.4 | 2024-01-08 | 43.8 |
| 2024-03-18 | 40.4 | 2024-01-05 | 44.5 |
Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Harbin Gloria Pharmaceuticals Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000QG8
Share Class Description:
SZSE:002437: Class ACompare
Compare
Traded in other countries / regions
002437.China IPO Date
2010-06-23Description
Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers